Promises and challenges of genetic therapy for blindness

The Lancet

Volumn 374, Issue 9701, 2009, Pages 1569-1570

  Cremers, Frans PM ^a,b   Collin, Rob WJ ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EYE PROTEIN; PARVOVIRUS VECTOR; RETINAL PIGMENT EPITHELIUM 65 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; DISEASE SEVERITY; DRUG SAFETY; GENE MUTATION; GENE THERAPY; GENOMICS; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LEBER CONGENITAL AMAUROSIS; NONHUMAN; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ANIMALS; CARRIER PROTEINS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; EYE PROTEINS; GENE THERAPY; GENETIC VECTORS; HUMANS; INFANT, NEWBORN; MICE; MUTATION; OPTIC ATROPHY, HEREDITARY, LEBER;

EID: 70350619337     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61869-9     Document Type: Note

References (12)

1. Bainbridge J.W.B., Smith A.J., Barker S.S., et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008) 2231-2239
2. Maguire A.M., Simonelli F., Pierce E.A., et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008) 2240-2248
3. Cideciyan A.V., Aleman T.S., Boye S.L., et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105 (2008) 15112-15127
4. Yzer S., van den Born L.I., Schuil J., et al. A Tyr368His RPE65 founder mutation is associated with early-onset retinal dystrophy with variable expression and progression in 10 families of a genetically isolated population. J Med Genet 40 (2003) 709-713
5. Maguire A.M., High K.A., Auricchio A., et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 10.1016/S0140-6736(09)61836-5 published online Oct 24.
6. Dejneka N.S., Surace E.M., Aleman T.S., et al. In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther 9 (2004) 182-188
7. Acland G.M., Aguirre G.D., Bennett J., et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12 (2005) 1072-1082
8. Cideciyan A.V., Hauswirth W.W., Aleman T.S., et al. Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 361 (2009) 725-727
9. den Hollander A.I., Roepman R., Koenekoop R.K., and Cremers F.P.M. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res 27 (2008) 391-419
10. Welch E.M., Barton E.R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91
11. Hacein-Bey-Abina S., Garrigue A., Wang G.P., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118 (2008) 3132-3142
12. Howe S.J., Mansour M.R., Schwarzwaelder K., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118 (2008) 3143-3150